(Bloomberg Opinion) -- The Covid-19 pandemic arrested the plans of millions of Americans to purchase a home. But what if you lock someone down in a home they had already mentally moved out of? Might they pour their energy into touring homes online to produce a short list of targets? And might they get preapproved for a mortgage so it’s a simple matter of income verification once the economy reopened and they’d submitted an offer on a home?Of course they would, which helps explain the huge surge in the Mortgage Bankers Association of America’s index tracking applications for loans to buy homes. That gauge has risen for nine straight weeks to reach its highest level since the start of 2009, which defies logic when you consider that more than 44 million Americans have filed for unemployment benefits since mid-March. No doubt that some of this is tied to the minor exodus from...
Interactive Brokers Chief Strategist Steve Sosnick joins Yahoo Finance’s On The Move panel to discuss the unanticipated side effect of the fiscal stimulus....
Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa. The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price target. Stifel analyst Derek Archila reiterated a Hold rating.SVB Leerink analyst Ami Fadia has an Outperform rating and $9 price target.Settlement Could Move Sentiment For Amarin: The settlement agreement is good news, especially as it comes after Amarin lost the case with two other generic manufacturers, Hikma and Dr.Reddy's Laboratories Ltd (NYSE: RDY), Cantor's Chen said in a Tuesday note. If Apotex felt it had a chance, it would have waited a few months for a near-term opportunity rather than waiting until 2029, the analyst said. Amarin is appealing a patent invalidity ruling from March to the U.S. Court of Appeals, she said. "We think this settlement could potentially move...
Valero Energy Corporation (NYSE: VLO) shares are trading lower on Wednesday after Goldman Sachs downgraded the stock from Buy to Neutral and announced a price target of $68 per share.Valero Energy is one of the largest independent refiners in the U.S. It operates 14 refineries with a total throughput capacity of 3.1 million barrels a day in the U.S., Canada, and the U.K.Valero also owns 14 ethanol plants with a capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 275 million gallons per year of renewable diesel.Valero Energy shares were trading down 4.13% at $63.43 at time of publication on Wednesday. The stock has a 52-week high of $101.99 and a 52-week low of $31.Related Links:BP Cuts 10K Jobs As Coronavirus Hits Oil DemandUSO Tanks After Oil ETF's Temporary Trading HaltLatest Ratings for VLO DateFirmActionFromTo Jun 2020Goldman...
Livongo Health (NASDAQ: LVGO) shares are trading higher on Wednesday, potentially amid concerns of a resurgence in U.S. coronavirus cases. The coronavirus has been a positive catalyst for the digital health space.Livongo Health provides a data science and technology enabled platform for detection of diabetes. Its additional solutions include Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength.The company's clients comprise of employers, health plans, government entities, and labor unions. Its operations are primarily located in the U.S.Livongo Health shares were trading up 4.21% at $69.32 at time of publication on Wednesday. The stock has a 52-week high of $71.12 and a 52-week low of $15.12.Related Links:Livongo Health Shares Open Well Above IPO PriceLivongo Health IPO: What You Need To KnowSee more from Benzinga * Second Wave Of Coronavirus Hits China's Capital Beijing * Oracle Reports Mixed Q4 Earnings * Why Remark's Stock Is...
